84624-17-9

Basic information

• Product Name: FMOC-D-Valine
• Synonyms: (R)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-Methylbutanoic acid;Fmoc-D-Val-OH >=98.0% (HPLC);Fmoc-D-valine≥ 99% (HPLC);N-FMOC-D-VALINE;N-[(9H-FLUOREN-9-YLMETHOXY)CARBONYL]-D-VALINE;N-9-FLUORENYLMETHYLOXYCARBONYL-D-VALINE;N-(9-FLUORENYLMETHOXYCARBONYL)-D-VALINE;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-D-VALINE
• CAS NO: 84624-17-9
• Molecular Formula: C₂₀H₂₁NO₄
• Molecular Weight: 339.39
• EINECS: 1533716-785-6
• Product Categories: Fluorenes, Flurenones;Amino Acid Derivatives;Amino Acids;Valine [Val, V];Fmoc-Amino Acids and Derivatives;Amino Acids (N-Protected);Biochemistry;Fmoc-Amino Acids;Fmoc-Amino acid series
• Mol File: 84624-17-9.mol

Chemical Properties

• Melting Point: 143-144 °C(lit.)
• Boiling Point: 551.8±33.0 °C(Predicted)
• Appearance: white to light yellow crystal powder
• Density: 1.229±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), DMF (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 3.90±0.10(Predicted)
• Water Solubility: Solubility in methanol (almost transparency). Slightly soluble in water.
• BRN: 6489548
• CAS DataBase Reference: FMOC-D-Valine(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-D-Valine(84624-17-9)
• EPA Substance Registry System: FMOC-D-Valine(84624-17-9)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 84624-17-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
FMOC-D-Valine is used as a building block in the synthesis of peptides and pharmaceuticals for its ability to selectively inhibit fibroblasts and promote the growth of epithelial cells. This selective growth property makes it a valuable component in the development of drugs targeting specific cell types.
Used in Cancer Research:
FMOC-D-Valine is used as a component in the structure of Actinomycin D, an antitumor drug, for its potential role in cancer treatment. Its presence in this drug highlights its importance in the development of cancer therapies and understanding its mechanism of action in inhibiting tumor growth.
Used in Peptide Synthesis:
FMOC-D-Valine is used as a protected amino acid in peptide synthesis, allowing for the efficient and selective incorporation of D-Valine into peptide sequences. The N-Fmoc protection group ensures that the amino acid remains stable during the synthesis process, facilitating the production of desired peptide structures.

Upstream product

• 640-68-6 D-Val-OH 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 24324-17-2 9-Fluorenylmethanol 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 759-05-7 3-methyl-2-ketobutanoic acid 
• 126727-02-4 Fmoc-valine 
• 516-06-3 D,L-valine 

Downstream Products

• 92466-88-1 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-methyl-butyric acid 2,4,5-trichloro-phenyl ester 
• 84624-19-1 N^α-Fmoc-D-Val-Leu benzyl ester 
• 84624-18-0 N^α-Fmoc-D-Val-Leu-N^ε-Fmoc-Lys benzyl ester 
• 136554-82-0 (R)-3-[(R)-2-Amino-3-(1H-indol-3-yl)-propionylamino]-N-{(S)-1-[(R)-1-((S)-1-hydrazinocarbonyl-3-methyl-butylcarbamoyl)-2-methyl-propylcarbamoyl]-3-methyl-butyl}-succinamic acid tert-butyl ester 
• 182952-86-9 N-(9-fluorenylmethoxycarbonyl)-D-valine-(4-methoxybenzyl) ester 
• 180973-30-2 (S)-2-((2S,3R)-2-{(S)-2-[(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-methyl-butyrylamino]-3-tritylsulfanyl-propionylamino}-3-hydroxy-butyrylamino)-3-methyl-butyric acid methyl ester 
• 183444-87-3 D-(N-9-fluorenylmethoxycarbonylvalyl)-L-leucine tert-butyl ester 
• 1026426-38-9 (R)-3-[(R)-2-Amino-3-(1H-indol-3-yl)-propionylamino]-N-{(S)-1-[(R)-1-((S)-1-hydrazinocarbonyl-3-methyl-butylcarbamoyl)-2-methyl-propylcarbamoyl]-2-phenyl-ethyl}-succinamic acid tert-butyl ester 
• 198545-90-3 Fmoc-D-Val-Cl 
• 327187-74-6 N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-valyl-prolyl-sarcosine tert-butyl ester 
• 620567-53-5 N-α-(fluorenylmethoxy)carbonyl-D-valyl-(S-triphenylmethyl)-D-cysteinyl-(O-t-butyldimethylsilyl)-L-threonine methyl ester 
• 620567-59-1 N-α-(fluorenylmethoxy)carbonyl-D-valyl-D-valyl-(S-triphenylmethyl)-D-cysteinyl-(O-t-butyldimethylsilyl)-L-threonine methyl ester 
• 640722-86-7 (R)-2-[(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-methyl-butyrylamino]-3-tritylsulfanyl-propionic acid allyl ester 

Relevant articles and documents

Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety

Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.

Determination of Chemical and Enantiomeric Purity of α-Amino Acids and their Methyl Esters as N-Fluorenylmethoxycarbonyl Derivatives Using Amylose-derived Chiral Stationary Phases

Liquid chromatographic enantiomer separation and simultaneous determination of chemical and enantiomeric purity of α-amino acids and their methyl esters as N-fluorenylmethoxycarbonyl (FMOC) derivatives was performed on three covalently bonded type chiral stationary phases (CSPs) derived from amylose derivatives. The enantiomer separation of α-amino acid esters as N-FMOC derivatives was better than that of the corresponding acids, especially for CSP 1 and 2. Chemical impurities as the corresponding racemic acids present in several commercially available racemic amino acid methyl esters were observed to be 0.49–17.50%. Enantiomeric impurities of several commercially available L-amino acid methyl esters were found to be 0.03–0.58%, whereas chemical impurities as the corresponding racemic acids present in the same analytes were found to be 0.13–13.62%. This developed analytical method will be useful for the determination of chemical and enantiomeric purity of α-amino acids and/or esters as N-FMOC derivatives using amylose-derived CSPs.

Structure-guided engineering of: Meso -diaminopimelate dehydrogenase for enantioselective reductive amination of sterically bulky 2-keto acids

meso-Diaminopimelate dehydrogenase (DAPDH) and mutant enzymes are an excellent choice of biocatalysts for the conversion of 2-keto acids to the corresponding d-amino acids. However, their application in the enantioselective reductive amination of bulky 2-keto acids, such as phenylglyoxylic acid, 2-oxo-4-phenylbutyric acid, and indole-3-pyruvic acid, is still challenging. In this study, the structure-guided site-saturation mutagenesis of a Symbiobacterium thermophilum DAPDH (StDAPDH) gave rise to a double-site mutant W121L/H227I, which showed dramatically improved enzyme activities towards various 2-keto acids including these sterically bulky substrates. Several d-amino acids were prepared in optically pure form. The molecular docking of substrates into the active sites of wild-type and mutant W121L/H227I enzymes revealed that the substrate binding cavity of the mutant enzyme was reshaped to accommodate these bulky substrates, thus leading to higher enzyme activity. These results lay a foundation for further shaping the substrate binding pocket and manipulating the interactions between the substrate and binding sites to access highly active d-amino acid dehydrogenases for the preparation of synthetically challenging d-amino acids.

Chiral oxazoline NNP type ligands as well as synthesis method and application thereof

The invention relates to chiral oxazoline NNP type ligands as well as a synthesis method and an application thereof. The ligands adopt the structure shown in general formula 1 or 2. During preparation, a chiral ligand 1 and a chiral ligand 2 are prepared from Fmoc-Cl and a chiral amino acid compound 3 used as initial raw materials through multi-step reactions. The ligands can be applied to catalytic synthesis of chiral beta ketone ester fluoride and synthesis of propanedione derivatives and chiral malonate derivatives through palladium-catalyzed asymmetric allyl substitution reactions. Compared with the prior art, the reaction condition is mild, operation is easy, repeatability is good, mass preparation can be realized, and the prepared catalyst has higher ee value and yield when applied to beta ketone ester fluoridation and palladium-catalyzed asymmetric allyl substitution reactions.

Ureidopeptide-based Bronsted bases: Design, synthesis and application to the catalytic enantioselective synthesis of β-amino nitriles from (arylsulfonyl)acetonitriles

The addition of cyanoalkyl moieties to imines is a very attractive method for the preparation of β-amino nitriles. We present a highly efficient organocatalytic methodology for the stereoselective synthesis of β-amino nitriles, in which the key to success is the use of ureidopeptide-based Bronsted base catalysts in combination with (arylsulfonyl)acetonitriles as synthetic equivalents of the acetonitrile anion. The method gives access to a variety of β-amino nitriles with good yields and excellent enantioselectivities, and broadens the stereoselective Mannich-type methodologies available for their synthesis. Learning from peptides: A concise route for the catalytic enantioselective synthesis of β-amino nitriles has been achieved by using ureidopeptide-based Bronsted bases as catalysts in the Mannich reaction of N-Boc imines and (arylsulfonyl)acetonitriles (see scheme; Boc=tert-butoxycarbonyl, napht=naphthyl, TMS=trimethylsilyl).